Stock Analiz

Electromed, Inc. ELMD

Biotechnology: Electromedical & Electrotherapeutic Apparatus · IPO 2011 · data as of November 13, 2026

$24.32Market cap $199M
Open the interactive analysis →

Electromed, Inc. (ELMD) is a healthcare company listed in the US with a market value of about $199M. In the twelve months to September 30, 2026 it had revenue of $76M and net income of $12M, a net margin of 15.8%.

Its overall Stock Analiz score is 3.6 out of 5 (good). The strongest part is track record (5/5); the weakest is shareholder returns (2/5).

Key numbers: a P/E of 17.6, a price to free cash flow of 22.8, 5-year revenue growth of 16% a year, a 5-year average ROIC of 12%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 6% below the current price.

About Electromed

Electromed is listed in the US and classified in biotechnology: electromedical & electrotherapeutic apparatus, IPO year 2011. Revenue went from $19M in 2015 to $74M in 2026, growth of about 12.9% a year. It was profitable in 10 of the last 10 years in our data. It spends 2% of revenue on research and development.

Score: 3.6 / 5

Value3/5
Future growth3/5
Track record5/5
Financial health5/5
Shareholder returns2/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • Pays a dividend
  • Share count down over 3 years (buybacks)
  • Dividend 3 years in a row

Valuation

P/E (TTM)17.6
Forward P/E—
P/FCF22.8
P/S2.6
P/B3.8
EV/EBITDA11.7
PEG0.48
Dividend yield0.00%
FCF yield4.4%
Shareholder yield2.0%
Intrinsic value vs. price−6%

Growth and quality

Revenue growth (1 yr)15.3%
Revenue growth (5 yrs, per year)15.6%
EPS growth (5 yrs, per year)36.9%
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)9.7%
ROIC (5-yr avg.)12.4%
Profitable years (of last 10)10
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2026202520242023202220212020201920182017
Revenue$76M$74M$64M$55M$48M$42M$36M$32M$31M$28M$26M
Net income$12M$11M$8M$5M$3M$2M$2M$4M$2M$2M$2M
Free cash flow$9M$8M$11M$9M-$333000-$2M$3M$3M$1M$2M$572358
EPS (diluted)$1.38$1.30$0.85$0.58$0.36$0.26$0.27$0.47$0.23$0.21$0.26
Net margin15.8%15.3%11.8%9.4%6.6%5.5%6.6%12.8%6.3%6.5%8.6%
ROIC—20.2%16.3%10.8%8.2%6.7%7.2%13.4%7.4%7.7%10.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Electromed’s P/E ratio?

About 17.6, based on the last twelve months of diluted earnings per share.

Is Electromed stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 6% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Electromed pay a dividend?

Not currently.

Is Electromed a good stock to buy?

We do not give buy or sell advice. Electromed scores 3.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.